Patient preferences for glucagon-like peptide 1 receptor–agonist treatment attributes

References

• International Diabetes Federation (IDF)Diabetes atlas8th ed2017 Available from: http://www.diabetesatlas.org/resources/2017-atlas.htmlAccessed May 21, 2018
   Google Scholar
• PurnellTAJoySLittleEBridgesJFMaruthurNPatient preferences for noninsulin diabetes medications: a systematic reviewDiabetes Care20143772055206210.2337/dc13-252724963113
   PubMed Web of Science ®Google Scholar
• DaviesMJD’AlessioDAFradkinJManagement of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care201841122669270110.2337/dci18-003330291106
   PubMed Web of Science ®Google Scholar
• National Institute of Health and Care ExcellenceType 2 diabetes in adults: managementNICE guideline 28122015 Available from: https://www.nice.org.uk/guidance/ng28Accessed May 24, 2018
   Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• BridgesJFOnukwughaEJohnsonFHauberAPatient preference methods – A patient centered evaluation paradigmISPOR Connections200713647 Available from: https://www.ispor.org/news/articles/Dec07/Bridgesetal2007-Patientpreferencemethods.pdfAccessed May 24, 2018
   Google Scholar
• HauberABHanSYangJ-CEffect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetesPatient Prefer Adherence2013793794910.2147/PPA.S4346524086104
   PubMed Web of Science ®Google Scholar
• García-PérezLEAlvarezMDillaTGil-GuillénVOrozco-BeltránDAdherence to therapies in patients with type 2 diabetesDiabetes Ther20134217519410.1007/s13300-013-0034-y23990497
   PubMed Web of Science ®Google Scholar
• Kennedy-MartinTBoyeKSPengXCost of medication adherence and persistence in type 2 diabetes mellitus: a literature reviewPatient Prefer Adherence2017111103111710.2147/PPA.S13479228721024
   PubMed Web of Science ®Google Scholar
• BridgesJFPHauberABMarshallDConjoint analysis applications in health – a checklist: a report of the ISPOR good research practices for conjoint analysis task forceValue Health201114440341310.1016/j.jval.2010.11.01321669364
   PubMed Web of Science ®Google Scholar
• StewartKDJohnstonJAMatzaLSPreference for pharmaceutical formulation and treatment process attributesPatient Prefer Adherence2016101385139910.2147/PPA.S10182127528802
   PubMed Web of Science ®Google Scholar
• MatzaLSBoyeKSStewartKDDaviesEWPaczkowskiRHealth state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetesBMC Health Serv Res201717177410.1186/s12913-017-2648-729178918
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (ADA)Pharmacologic approaches to glycemic treatment: standard of medical care in diabetes – 2018Diabetes Care201841suppl 1S73S8510.2337/dc18-073329222379
   PubMed Web of Science ®Google Scholar
• LevinPANguyenHWittbrodtETKimSCGlucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness researchDiabetes Metab Syndr Obes20171012313910.2147/DMSO.S13083428435305
   PubMed Web of Science ®Google Scholar
• QinLChenSFloodEGlucagon-like peptide-1 receptor agonist treatment attributes important to injection-naive patients with type 2 diabetes mellitus: a multinational preference studyDiabetes Ther20178232133410.1007/s13300-017-0230-228155131
   PubMed Web of Science ®Google Scholar
• BienDRDannerMVennedeyVCivelloDEversSMHiligsmanMPatients’ preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experimentsPatient201710555356510.1007/s40271-017-0235-y28364387
   PubMedGoogle Scholar
• PoonJLBoyeKSThieuVTNorrbackaKHassanSWGelhornHLPreferences for attributes of medications among patients with type 2 diabetes: a cross-medication class comparison of injection therapiesCurr Res Diabetes Obesity J201865555700 EPub ahead of print
   Google Scholar
• GelhornHLPoonJLDaviesEWPaczkowskiRCurtisSEBoyeKSEvaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UKPatient Prefer Adherence201591611162210.2147/PPA.S8244126635470
   PubMed Web of Science ®Google Scholar
• GelhornHLBacciEDPoonJLBoyeKSSuzukiSBabineauxSMEvaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in JapanPatient Prefer Adherence2016101337134810.2147/PPA.S10928927524889
   PubMed Web of Science ®Google Scholar
• HauberABNguyenHPosnerJKalsekarIRugglesJA discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetesCurr Med Res Opin201632225126210.1185/03007995.2015.111743326549576
   PubMed Web of Science ®Google Scholar
• MatzaLSBoyeKSJordanJBPatient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetesPatient Prefer Adherence20181297197910.2147/PPA.S17606729922043
   PubMed Web of Science ®Google Scholar
• PolsterMZanuttoEMcDonaldSConnerCHammerMA comparison of preferences for two GLP-1 products – liraglutide and exenatide – for the treatment of type 2 diabetesJ Med Econ201013465566110.3111/13696998.2010.52937721034377
   PubMedGoogle Scholar
• QinLChenSFloodEGlucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United KingdomDiabetes Ther20178233535310.1007/s13300-017-0237-828236271
   PubMed Web of Science ®Google Scholar
• JendleJTorffvitORidderstraleMEricssonANilsenBBogelundMWillingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme resultsJ Med Econ201215suppl 21510.3111/13696998.2012.703633
   PubMedGoogle Scholar
• RydénAChenSFloodERomeroBGrandySDiscrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with type 2 diabetes mellitusPatient201710447548710.1007/s40271-017-0225-028315192
   PubMedGoogle Scholar
• BoyeKSMatzaLSWalterKNVan BruntKPalsgroveACTynanAUtilities and disutilities for attributes of injectable treatments for type 2 diabetesEur J Health Econ201112321923010.1007/s10198-010-0224-820224930
   PubMed Web of Science ®Google Scholar
• OttoTStralkaRSchimmelpfenningHJungHBrunsKUmstellung von oralen auf injektable antidiabetika bei fort schreitendem typ-2-diabetes: welche präferenzen haben die patienten? [Treatment options for patients with progressing type 2 diabetes: what are patients’ preferences in Germany when switching from oral to injectable antidiabetic medication]Gesundh Okön Qual Manag201621181198 German
   Google Scholar
• MatzaLSBoyeKSCurrieBMPatient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetesCurr Med Res Opin20183481457146410.1080/03007995.2018.146590329661026
   PubMed Web of Science ®Google Scholar
• JoySMLittleEMauthurNMPurnellTSBridgesJFPatient preferences for the treatment of type 2 diabetes mellitus: a scoping reviewPharmacoeconomics2013311087789210.1007/s40273-013-0089-724081453
   PubMed Web of Science ®Google Scholar